检索结果-南通市图书馆

tenofovir rescue therapy in pregnant females with chronic hepatitis B

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第8期21卷 2504-2509页

作者： Yu-Hong Hu Min Liu Wei Yi Yan-Jun Cao Hao-Dong Cai Department of Hepatology Beijing Ditan Hospital Capital Medical University

AIM:To evaluate the safety and efficacy of tenofovir monotherapy in pregnant females resistant to lamivudine or *** effect of tenofovir on the fetus was also ***:The clinical data of 17 females were reviewed in this *** events and pregnancy outcomes from January 1,2011 to June 30,2013 were evaluated in the Department of Gynecology and Obstetrics of BeijingDitan Hospital,Capital Medical University,Beijing,*** pregnant females developed lamivudine(LAM)-or telbivudine(Ld T)-resistant chronic hepatitis B and received tenofovir(TDF)therapy(300 mg/d),and its curative effect,maternal and perinatal adverse events,fetal growth and development,and neonatal prognosis were ***:The median hepatitis B virus(HBV)DNA level in the pregnant females with LAM or Ld T resistance was 5.9(range,4.2-7.2)log10 copies/m L before the initiation of *** of these females had abnormal alanine aminotransferase(ALT)*** patients were treated with TDF for a median of 24 wk(range,12-40 wk).Fourteen females(82.4%)had an HBV DNA level of<500 copies/m L at the time of *** decrease was statistically significant(P<0.0001).Serum ALT levels were normalized in all subjects with an elevated serum ALT level at baseline(P=0.0003).There were no significant changes in serum creatinine and phosphorus levels during TDF *** addition,no adverse events related to TDF treatment were *** females delivered 17 live infants,and all infants had good Apgar *** mean birth weight was 3226.5±331.7 g,and the mean length at birth was 50.4±1.1 *** growth and development of the infants was normal at birth,and no infants had birth defects related to TDF *** infants completed HBV vaccination and had no evidence of vertical ***:The use of TDF in pregnant females with chronic HBV and LAM or Ld T resistance was safe and effective.

关键词： Pregnancy Chronic hepatitis B tenofovir Safety Bir

tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2019年第33期25卷 4985-4998页

作者： Won Hyeok Choe Kijeong Kim So-Young Lee Yu-Min Choi So Young Kwon Jeong Han Kim Bum-Joon Kim Department of Internal Medicine Konkuk University School of MedicineSeoul 05030South Korea Department of Microbiology College of MedicineChung-Ang UniversitySeoul 06974South Korea Department of Biomedical Sciences Microbiology and ImmunologyLiver Research InstituteCancer Research Institute and SNUMRCCollege of MedicineSeoul National UniversitySeoul 03080South Korea

BACKGROUND Hepatitis B virus(HBV) DNA polymerase mutations usually occur to long term use of nucleos(t)ide analogues(NAs), but they can occur spontaneously in treatment-na?ve chronic hepatitis B(CHB) patients. The naturally occurring HBV DNA polymerase mutations might complicate antiviral therapy with NAs,leading to the generation of drug-resistant viral mutants and disease *** most common substitutions are known to be YMDD-motif mutations, but their prevalence and the influence on antiviral therapy is *** To investigate prevalence of the naturally occurring rtM204I mutations in treatment-na?ve CHB genotype C2 patients and their influence on antiviral *** A total of 410 treatment-na?ve CHB patients infected with HBV genotype C2 strains were enrolled in this retrospective study. Among the 410 patients, 232 were treated with NAs for at least 12 mo. Significant fibrosis was defined as fibrosis-4 index > 3.25 or aspartate aminotransferase to platelet ratio index > *** viral response(CVR) during NAs was defined as undetectable serum HBV DNA(tenofovir achieved CVR at 12 mo of tenofovir, irrespective of pre-existence of naturally occurring rtM204I mutations(CVR rates: patients with

关键词： Chronic hepatitis B Entecavir Hepatitis B virus Liver fibrosis Mutation tenofovir

tenofovir vs lamivudine plus adefovir in chronic hepatitis B:TENOSIMP-B study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2017年第41期23卷 7459-7469页

作者： Manuel Rodríguez Juan Manuel Pascasio Enrique Fraga Javier Fuentes Martín Prieto Gloria Sánchez-Antolín Jose Luis Calleja Esther Molina María Luisa García-Buey María Angeles Blanco Javier Salmerón María Lucía Bonet Jose Antonio Pons Jose Manuel González Miguel Angel Casado Francisco Jorquera 无 Division of Gastroenterology and Hepatology.Hospital Universitario Central de Asturias Unit for the Clinical Management of Digestive Diseases IBISHospital Universitario Virgen del Rocío Liver Transplantation and Hepatology Unit Gastroenterology ServiceHospital Universitario Reina Sofía Digestive Medicine Service Hospital Universitario Miguel Servet Hepatology Unit Digestive Medicine ServiceHospital Universitari i Politècnic La Fe Hepatology Unit Hospital Universitario Rio Hortega Liver Unit Hospital Universitario Puerta de Hierro de MajadahondaUniversidad Autónoma de Madrid Digestive Medicine Service Hospital Clínico de Santiago de Compostela Liver Unit Hospital Universitario de La Princesa Digestive Medicine Service Hospital General Universitario Gregorio Maranon Digestive Medicine Unit Complejo Hospitalario de Granada Digestive Medicine Service Hospital Universitario Son Espases Hepatology Unit IMIB Hospital Universitario Virgen de la Arrixaca Digestive Medicine Service Hospital Clínico Universitario de Valladolid Pharmacoeconomics and Outcomes Research Iberia Division of Gastroenterology and Hepatology Complejo Asistencial Universitario de León the TENOSIMP-B Research Group

AIM To demonstrate the non-inferiority(15% non-inferiority limit) of monotherapy with tenofovir disoproxil fumarate(TDF) vs the combination of lamivudine(LAM) plus adefovir dipivoxil(ADV) in the maintenance of virologic response in patients with chronic hepatitis B(CHB) and prior failure with *** This study was a Phase IV prospective, randomized, open, controlled study with 2 parallel groups(TDF and LAM+ADV) of adult patients with hepatitis B e antigen(HBe Ag)-negative CHB, prior failure with LAM, on treatment with LAM+ADV for at least 6 mo, without prior resistance to ADV and with an undetectable viral load at the start of the study, in 14 Spanish hospitals. The follow-up time for each patient was 48 wk after randomization, with quarterly visits in which the viral load, biochemical and serological parameters, adverse effects, adherence to treatment and consumption of hospital resources were *** Forty-six patients were evaluated [median age: 55.4 years(30.2-75.2); 84.8% male], including 22 patients with TDF and 24 with LAM+ADV. During study development, hepatitis B virus DNA(HBV-DNA) remained undetectable, all patients remained HBe Ag negative, and hepatitis B surface antigen(HBs Ag) positive. Alanine aminotransferase(ALT) values at the end of the study were similar in the 2 groups(25.1± 7.65, TDF vs 24.22 ± 8.38, LAM+ADV, P = 0.646). No significant changes were observed in creatinine or serum phosphorus values in either group. No significant differences between the 2 groups were noted in the identification of adverse effects(AEs)(53.8%, TDF vs 37.5%, LAM+ADV, P = 0.170), and none of the AEs which occurred were serious. Treatment adherence was 95.5% and 83.3% in the TDF and the LAM+ADV groups, respectively(P = 0.488). The costs associated with hospital resource consumption were significantly lower with the TDF treatment than the LAM+ADV treatment(€4943 ± 1059 vs €5811 ± 1538, respectively, P < 0.001).CONCLUSION TDF monotherapy proved to be safe

关键词： tenofovir Lamivudine+Adefovir Efficacy Safety Adherence Costs Hepatitis B

tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第9期21卷 2746-2753页

作者： Dan-Hong Yang Yuan-Jun Xie Nian-Feng Zhao Hong-Ying Pan Ming-Wei Li Hai-Jun Huang Department of Infectious Diseases Zhejiang Provincial People’s Hospital The Third Affiliated Hospital of Zhejiang Chinese Medical University Department of Infectious Diseases The First Affiliated HospitalCollege of MedicineZhejiang University

AIM:To assess the efficacy of tenofovir disoproxil fumarate(TDF) in lamivudine(LAM)-resistant patients with a suboptimal response to LAM plus adefovir(ADV).METHODS:We retrospectively analyzed the efficacy of switching to tenofovir disoproxil fumarate in suboptimal responders to lamivudine plus *** were reviewed for LAM-resistant chronic hepatitis B(CHB) patients who visited the Zhejiang Province People's Hospital and The First Affiliated Hospital,College of Medicine,Zhejiang University,from June 2009 to May *** whose serum hepatitis B virus(HBV) DNA remained detectable despite at least 6 mo of LAM plus ADV combination therapy were *** with a suboptimal response to LAM plus ADV were randomized to switch to TDF monotherapy(300 mg/d orally; TDF group) or to continuation with LAM(100 mg/d orally) plus ADV(10 mg/d orally; LAM plus ADV group) and were followed for 48 *** HBV DNA was determined at baseline and weeks 4,12,24,36,and *** serological markers and biochemistry were assessed at baseline and weeks 12,24,and *** surveillance and side effects were monitored during ***:Fifty-nine patient were randomized to switch to TDF(n =28) or continuation with LAM plus ADV(n =31).No significant differences were found between the groups at *** to TDF therapy,all patients had been exposed to LAM plus ADV for a median of 11 mo(range:6-24 mo).No difference was seen in baseline serum HBV DNA between the two groups [5.13 ± 1.08 log10 copies/m L(TDF) vs 5.04 ± 31.16 log10 copies/m L(LAM +ADV),P =0.639].There was no significant difference in the rates of achieving complete virological response(CVR) at week 4 between the TDF and LAM +ADV groups(17.86% vs 6.45%,P =0.24).The rate of achieving CVR in the TDF and LAM plus ADV groups was 75% vs 16.13% at week 12,82.14% vs 22.58% at week 24,89.29% vs 25.81% at week 36,and 96.43% vs 29.03% at week 48,respectively(P < 0.001).The rate of alanine aminotransferase normaliza

关键词： Hepatitis B virus Adefovir Lamivudine tenofovir di

Comparing the Efficacy and Safety of Treating Chronic Hepatitis B Infection during Pregnancy with Lamivudine,Telbivudine,and tenofovir:A Meta-analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2019年第3期7卷 197-212页

作者： Shahnaz Sali Mohammad Darvishi Mojtaba GhasemiAdl Meisam Akhlaghdoust Azin Mirzazadeh Somayeh Elikaei Behjati Hossein Sheikh-Zeinolabedini Shervin Shokouhi Soheil Tavakolpour Infectious Diseases and Tropical Medicine Research Center Shahid Beheshti University of Medical SciencesTehranIran Department of Aerospace and Subaquatic Medicine Infectious Diseases and Tropical Medicine Research Center(IDTMRC)AJA University of Medical SciencesTehranIran Pharmaceutical Sciences Research Center Tehran University of Medical SciencesTehranIran Pars Advanced and Minimally Invasive Medical Manners Research Center Pars HospitalIran University of Medical SciencesTehranIran Joint Bioinformatics Graduate Program University of Arkansas Little Rock and University of Arkansas for Medical SciencesLittle RockARUSA The Genetics Department at Islamic Azad University Science and Research BranchTehranIran Infectious Diseases and Tropical Medicine Research Center Shahid Beheshti University of Medical SciencesTehran 198396-3113Iran

Background and Aims:The perinatal transmission of hepatitis B virus(HBV)remains an important global health ***,a systematic review and meta-analysis were conducted to evaluate the evidence regarding the efficacy and maternal/fetal safety of treating pregnant women with lamivudine,telbivudine(LdT),and tenofovir(TDF).Methods:A PubMed and Scopus search resulted in 1,076 records,which were reduced to 36,containing 7,717 pregnant women with chronic HBV infection and 7467 infants meeting the inclusion *** latest search was in August ***:Treatment with LdT,but not lamivudine and TDF,could significantly reduce the hepatitis B virus surface antigen-positive rate(odds ratio(OR)=0.37)in infants;it also led to higher rates of hepatitis B e antigen loss(OR=12.14),hepatitis B e antigen seroconversion(OR=8.93),and alanine aminotransferase normalization in mothers(OR=1.49).Each of these treatments was able to significantly reduce HBV DNA positivity at birth(total OR=0.19)and mother-to-child-transmission of HBV(total OR=0.15),and to cause higher rates of HBV DNA suppression in mothers(total OR=25.53).However,nucleos(t)ide analogues might also be involved in creatine kinase elevation(total OR=7.48).In contrast,no significant association was found between nucleos(t)ide analogue therapy and preterm/premature births,congenital malformation,low birth weight,and abortion or fetal/infant *** results suggested LdT's high capability of preventing ***,TDF failed to show significant associations to a reduced risk of mother-to-child-transmission,probably due to the low number of patients ***:Although using either lamivudine,LdT,orTDF could lead to more favorable maternal/fetal outcomes,LdT seemed to show more potential in resolving certain infant-and maternal-related *** studies on the safety profile of such treatments are required.

关键词： Hepatitis B virus Antiviral therapy tenofovir Telbivudine Lamivudine Nucleos(t)ide analogues Pregnancy

Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2019年第23期25卷 2961-2972页

作者： Hyo-Young Lee Hyunwoo Oh Chan-Hyuk Park Yee-Hui Yeo Mindie H Nguyen Dae-Won Jun Department of Internal Medicine Hanyang University College of MedicineSeoul 04763South Korea Department of Internal Medicine Hanyang University Guri HospitalHanyang University College of MedicineGuri 11923South Korea Division of Gastroenterology and Hepatology Stanford University Medical CenterStanford UniversityStanford 94305CAUnited States

BACKGROUND Recently, the American Association for the Study of Liver Disease suggested no preference between tenofovir(TDF) and entecavir(ETV) regarding potential long-term risks of renal complications. Over the years, renal safety has become a critical concern in nucleos(t)ide analog-treated patients due to the long-term use of these drugs. However, existing studies do not show significant differences in renal dysfunction between these two drugs. Further, there is a paucity of studies comparing the long-term renal effects of TDF and *** To investigate the effects of TDF and ETV on renal function, we performed systematic review and *** Two investigators independently searched the Cochrane Library, MEDLINE, and Embase databases for randomized controlled trials and nonrandomized studies(NRSs) using the keywords 'CHB', 'tenofovir', and 'Entecavir', and additional references were obtained from the bibliographies of relevant articles published through December 2017. The quality of each study was assessed using the Newcastle-Ottawa scale and the Grading of Recommendations Assessment,Development and Evaluation criteria. The primary outcome was the change in serum creatinine level in the TDF and ETV groups at baseline, 6 mo, 12 mo and24 *** NRSs comprising 2263 participants met the inclusion criteria. Changes in creatinine levels were higher in the TDF group than in the ETV group at 6 mo[mean difference(MD) = 0.03 mg/dL;95%CI: 0.02-0.04;I2 = 0%], 12 mo(MD =0.05 mg/dL;95%CI: 0.02-0.08;I2 = 78%), and 24 mo(MD = 0.07 mg/dL;95%CI:0.01-0.13;I2 = 93%). The change in estimated glomerular filtration rate(eGFR) was significantly higher in the TDF group than in the ETV group at 6 mo[standardized mean difference(SMD),-0.22;95%Cl:-0.36--0.08;I2 = 0%], 12 mo(SMD =-0.24;95%Cl:-0.43--0.05;I2 = 50%), and 24 mo(-0.35;95%Cl:-0.61--0.09;I2= 67%).CONCLUSION TDF statistically significantly increased serum creatinine levels and decreased the eGFR in 6-24 mo compa

关键词： Hepatitis B Chronic tenofovir Entecavir Safety Review Systematic Meta-analysis

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2013年第48期19卷 9377-9382页

作者： Mustafa Kemal Celen Duygu Mert Müzeyyen Ay Tuba Dal Safak Kaya Necmettin Yildirim Serda Gulsun Tunga Barcin Sevgi Kalkanli Mehmet Sinan Dal Celal Ayaz Department of Infectious Diseases Faculty of Medicine Dicle University 21280 YenisehirDiyarbakir Turkey State Hospital 72000 Merkez Batman Turkey State Hospital Kiziltepe 47500 Mardin Turkey Department of Medical Microbiology Faculty of Medicine Dicle University 21280 Yenisehir Diyarbakir Turkey Department of Infectious Disease Teaching and Research Hospital 21100 Diyarbakir Turkey Department of Infectious Diseases State Hospital 47000 Mardin Turkey Department of Infectious Diseases State Hospital 21100 Diyarbakir Turkey Department of Infectious Diseases Mardin Park Hospital 47000 Mardin Turkey Department of Immunology Faculty of Medicine Dicle University 21280 Yeni?ehir Diyarbakir Turkey Department of Internal Medicine Faculty of Medicine Dicle University 21280 Yenisehir Diyarbakir Turkey

AIM:To evaluate the effects of tenofovir disoproxil fumarate(TDF)use during late pregnancy to reduce hepatitis B virus(HBV)transmission in highly viremic ***:This retrospective study included 45 pregnant patients with hepatitis B e antigen(+)chronic hepatitis B and HBV DNA levels>107copies/mL who received TDF 300 mg/d from week 18 to 27 of gestation(n=21).Untreated pregnant patients served as controls(n =24).All infants received 200 IU of hepatitis B immune globulin(HBIG)within 24 h postpartum and 20μg of recombinant HBV vaccine at 4,8,and 24 *** transmission rate was determined by hepatitis B surface antigen and HBV DNA results in infants at week ***:At week 28,none of the infants of TDFtreated mothers had immunoprophylaxis failure,whereas2(8.3%)of the infants of control mothers had immunoprophylaxis failure(P=0.022).There were no differences between the groups in terms of adverse events in mothers or congenital deformities,gestational age,height,or weight in *** postpartum week 28,significantly more TDF-treated mothers had levels of HBV DNA<250 copies/mL and normalized alanine aminotransferase compared with controls(62%vs none,P<0.001;82%vs 61%,P=0.012,respectively).CONCLUSION:TDF therapy during the second or third trimester reduced perinatal transmission rates of HBV and no adverse events were observed in mothers or infants.

关键词： Hepatitis B tenofovir Reverse transcriptase inhibitors Vertical transmission Chronic

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第18期21卷 5524-5531页

作者： Calvin Q Pan Sing Chan Huy Trinh Alan Yao Ho Bae Lillian Lou Division of Gastroenterology Department of Medicine New York University Langone Medical Center New York University School of Medicine Sing Chan Endoscopy FlushingNew York City NY 11355 United States San Jose Gastroenterology San Jose Ca 95128 United States AE and LY Medical associates Flushing New York City NY 11355 United States Asian Pacific Liver Center St. Vincent Medical Center Nexus Development Palo alto Ca 94301 United States

AIM:To compare the efficacy and safety of tenofovir disoproxil fumarate(TDF)in Asian and non-Asian chronic hepatitis B(CHB)***:The efficacy and safety of the initial 48wk of treatment with TDF was compared in a posthoc analysis of combined data from 217 Asians and299 non-Asians included in Studies 102 and 103and a post-approval,open-label trial(Study 123).Patient groups were compared according to baseline hepatitis B e antigen(HBe Ag)status and viral *** main outcome measures included the proportion of patients who achieved a hepatitis B virus(HBV)DNA level<400 copies/m L at Week 48 of *** measures included:HBV DNA and alanine aminotransaminase(ALT)levels over time;proportion of patients with normal ALT levels;proportion of patients with HBe Ag loss/seroconversion and proportion of patients with hepatitis B surface antigen loss/seroconversion;changes in liver *** and tolerability were evaluated by the occurrence of adverse events(AEs),serious AEs,laboratory abnormalities,discontinuation of the study drug due to AEs,or *** primary efficacy and safety analysis set included all patients who were randomly assigned to treatment and received at least one dose of study ***:At week 48,similar proportions of Asians and non-Asians reached HBV DNA<400 copies/m L(96%of Asian and 97%of non-Asian patients with HBe Ag-negative CHB and 83%of Asian and 79%of non-Asian patients with HBe Ag-positive CHB had HBV DNA)and normal ALT(78%of Asian and 81%of nonAsian patients with HBe Ag-negative CHB and 71%of Asian and 74%of non-Asian patients with HBe Agpositive CHB had normal ALT).On-treatment HBV DNA decline rates were similar between Asians and nonAsians regardless of baseline HBe Ag status and *** DNA decline during the first four weeks was2.9 log10 copies/m L in HBe Ag-negative Asians and nonAsians,and in HBe Ag-positive non-Asians,and 3.1log10 copies/m L in HBe Ag-positive *** Ag loss and seroconversion wa

关键词： Chronic hepatitis B tenofovir Asian patients Fibrosis High viral load

Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2018年第13期6卷 671-674页

作者： Jian-Chun Lu Long-Gen Liu Lin Lin Shu-Qin Zheng Yuan Xue Department of Liver Diseases the Third People’s Hospital of Changzhou Institute of Hepatology the Third People’s Hospital of Changzhou Department of Pharmacy the Third People’s Hospital of Changzhou

tenofovir disoproxil fumarate(TDF)is a potent nucleotide analogue with high barrier to resistance,which is recommended for multi-drug resistant hepatitis B virus(HBV)***,nephrotoxicity has been reported during TDF treatment,and tenofovir alafenamide(TAF),which has comparable efficacy to TDF and improves bone and renal safety,can be used as a replacement ***,we describe a clinical case concerning a 60-year-old individual suffering liver cirrhosis and renal dysfunction,and being infected with multidrug-resistant *** failing treatment with TDF,he received TAF as a rescue *** effectively inhibited HBV replication without worsening renal function or serum phosphorus ***,hepatocellular carcinoma(HCC)occurred during TAF treatment despite controlling the viral *** risk of HCC could not be eliminated and should be monitored during TAF treatment.

关键词： tenofovir alafenamide Disoproxil fumarate Hepatocellular carcinoma Hepatitis B virus Mutation